Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

(2020) Man Yee Keung et al.   Journal of Clinical Medicine

Biological Functions of Autophagy Genes: A Disease Perspective

(2019) Beth Levine et al.   CELL

Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma

(2019) Wenjing Zai et al.   CARCINOGENESIS

Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma

(2019) Yunxiang Ji et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

(2019) Paige Baldwin et al.   Frontiers in Oncology

Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion

(2018) Mario Mauthe et al.   Autophagy

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

(2018) Ewa Gogola et al.   CANCER CELL

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

(2018) Alan Ashworth et al.   Nature Reviews Clinical Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

High speed of fork progression induces DNA replication stress and genomic instability

(2018) Apolinar Maya-Mendoza et al.   NATURE

Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma

(2018) Xiaoxiong Wang et al.   Cell Death & Disease

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

(2017) Arnab Ray Chaudhuri et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma

(2017) V Colicchia et al.   ONCOGENE

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells

(2017) Pepijn M. Schoonen et al.   Nature Communications

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

(2017) Johann de Bono et al.   Cancer Discovery

trans-4,4’-Dihydroxystilbene (DHS) inhibits human neuroblastoma tumor growth and induces mitochondrial and lysosomal damages in neuroblastoma cell lines

(2017) Bhaskar Saha et al.   Oncotarget

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

(2017) Sergey Karakashev et al.   Cell Reports

SQSTM1/p62 mediates crosstalk between autophagy and the UPS in DNA repair

(2016) Graeme Hewitt et al.   Autophagy

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

PARP inhibitors: the journey from research hypothesis to clinical approval

(2015) Kishan AT Naipal et al.   Personalized Medicine

Loss of autophagy causes a synthetic lethal deficiency in DNA repair

(2015) Emma Y. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase

(2014) Kumar Somyajit et al.   CARCINOGENESIS

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib

(2014) Marine Gilabert et al.   PLoS One

Autophagy and genomic integrity

(2013) A T Vessoni et al.   CELL DEATH AND DIFFERENTIATION

Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

(2013) W. Wu et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?

(2013) Peter Bouwman et al.   CLINICAL CANCER RESEARCH

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

(2013) X Sui et al.   Cell Death & Disease

Mechanisms of Resistance to PARP Inhibitors—Three and Counting

(2013) Tito Fojo et al.   Cancer Discovery

Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells

(2012) Cuihong Zhou et al.   Autophagy

BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair

(2012) J. R. Chapman et al.   JOURNAL OF CELL SCIENCE

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

(2011) F. Rojo et al.   ANNALS OF ONCOLOGY

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

(2011) A. G. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells

(2010) P. Gottipati et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Methods in Mammalian Autophagy Research

(2010) Noboru Mizushima et al.   CELL

Autophagy in mammalian development and differentiation

(2010) Noboru Mizushima et al.   NATURE CELL BIOLOGY

Regulation Mechanisms and Signaling Pathways of Autophagy

(2009) Congcong He et al.   Annual Review of Genetics

Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells

(2008) F Scarlatti et al.   CELL DEATH AND DIFFERENTIATION

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE